RAMM Pharma Corp.
RAMM
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.40M | 2.71M | 2.95M | 3.19M | 3.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.40M | 2.71M | 2.95M | 3.19M | 3.19M |
| Cost of Revenue | 1.79M | 2.06M | 1.85M | 1.92M | 1.89M |
| Gross Profit | 605.10K | 646.10K | 1.10M | 1.28M | 1.30M |
| SG&A Expenses | 3.78M | 5.57M | 6.07M | 6.97M | 7.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 58.10K | 83.70K | 84.90K | 86.30K | 89.10K |
| Total Operating Expenses | 5.63M | 7.71M | 8.00M | 8.97M | 9.20M |
| Operating Income | -3.24M | -5.00M | -5.06M | -5.78M | -6.01M |
| Income Before Tax | -6.39M | -9.65M | -9.99M | -11.19M | -12.10M |
| Income Tax Expenses | 10.90K | 9.10K | 9.10K | -56.90K | 5.90K |
| Earnings from Continuing Operations | -6.40 | -9.66 | -10.00 | -11.13 | -12.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.40M | -9.66M | -10.00M | -11.13M | -12.11M |
| EBIT | -3.24M | -5.00M | -5.06M | -5.78M | -6.01M |
| EBITDA | -2.81M | -4.62M | -4.54M | -5.16M | -5.30M |
| EPS Basic | -0.05 | -0.08 | -0.08 | -0.09 | -0.10 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.08 | -0.08 | -0.09 | -0.10 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.56M |
| Average Diluted Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.56M | 477.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |